Executive summary
India regulates peptides under the Drugs and Cosmetics Act, 1940 (D&C Act) and the Drugs Rules, 1945. The CDSCO (Central Drugs Standard Control Organisation) and DCGI (Drugs Controller General of India) oversee drug approval and enforcement. India has a growing domestic peptide pharmaceutical manufacturing sector. The e-pharmacy regulatory framework remains draft since 2018.
Authorities and legal categories
CDSCO: central drug approval, clinical trial oversight, import licensing.
DCGI: head of CDSCO.
State Licensing Authorities: manufacturing and sale licensing, enforcement for e-pharmacies.
Key instruments:
Drugs and Cosmetics Act, 1940.
Drugs Rules, 1945.
New Drugs and Clinical Trials Rules, 2019 (NDCT Rules).
Drugs and Cosmetics (Amendment) Act, 2008 (Act 26 of 2008).
| Activity | Central authority | State role | Evidence to verify |
|---|---|---|---|
| New-drug approval | CDSCO and DCGI | No separate state approval role is established on this page | Current CDSCO drug register and exact product record |
| Clinical research | CDSCO authorization under the NDCT Rules | Ethics committee clearance is also required | Current regulatory and ethics records |
| Manufacturing | Central product status remains relevant | State Licensing Authorities issue manufacturing licences and enforce locally | Product approval and current central/state licences |
| Import | CDSCO handles import registration and the page-stated research or institutional permissions | State sale and pharmacy rules remain relevant after import | Exact form, permission, product, and importer record |
| Sale and e-pharmacy activity | Underlying central drug status still applies | State Licensing Authorities handle sale licensing and enforcement | Current product, pharmacy, prescription, and state records |
- Central CDSCO and DCGI: new-drug approval, clinical studies, and import licensing.
- State drug controllers: page-stated manufacturing, sale, and e-pharmacy enforcement roles.
- Both converge on product and activity status.
- Research import permission points only to an authorized research context, not consumer sale.
Approved medicines
Approved peptide medicines include Expansion of the abbreviation used in the monographs: glucagon-like peptide-1 receptor agonist. The atlas does not define the pharmacology of this class; see the monograph for what is documented about a specific compound. مصدر التعريف: Neutral gloss; the abbreviation is printed on the tirzepatide monograph but the atlas does not define the class pharmacology · المسرد (semaglutide/Ozempic, liraglutide, tirzepatide/Mounjaro), insulin analogues, teriparatide, octreotide, leuprolide, and desmopressin. Domestic semaglutide manufacturing was approved in 2025–2026 (Cipla, Sun Pharma, Dr Reddy's among applicants).
Source: CDSCO Drug Register, https://cdsco.gov.in
Investigational use
Clinical trials must comply with the NDCT Rules, 2019. Regulatory approval from CDSCO and ethics committee clearance are required. Form 11 allows import of small research quantities of new drugs without The fraction of an administered amount that reaches systemic circulation; for the intravenous route the atlas notes bioavailability is defined as complete. مصدر التعريف: Neutral gloss; usage context: Routes, devices, and absorption primer · المسرد/ bioequivalence data.
Compounding/manufacturing
Pharmacy compounding in India generally follows the D&C Act provisions for extemporaneous preparation. The scale of compounding is far smaller than in Western jurisdictions. Most peptides are manufactured products requiring manufacturing licence and drug approval.
Import
Unapproved drugs require CDSCO import registration.
Form CT-25 / NDCT Rules 86–88: this is not a general consumer pathway. The cited rules limit the route to a government hospital or government medical institution, for specified serious conditions, where the drug is approved in its country of origin, with Central Licensing Authority review. The full current rule and form control every eligibility and quantity limit.
Personal import of unapproved drugs is not permitted.
Research quantities can be imported under Form 11 for R&D purposes, not for consumer sale.
Online sale
The Draft e-Pharmacy Rules (2018) remain unfinalised as of August 2026.
Enforcement is via State Licensing Authorities under the D&C Act.
Online sale of prescription-only peptide medicines is legally restricted to registered pharmacies with a valid prescription. Many unregistered websites operate in a grey area.
| Permission | Does not confer | Source |
|---|---|---|
| Form 11 research import permission for institutional R&D | Consumer marketing authorization or permission to sell the research material as a medicine | CDSCO import/export materials and the current form |
| Online sale through a registered pharmacy under the underlying medicine rules | A separate medicine approval or an exemption for an unapproved product; the 2018 e-pharmacy rules remained draft as of 2026-08-06 | CDSCO and the applicable state record |
Research-use-only products
India does not recognise "research use only" as an exemption from drug regulation. Products marketed with therapeutic claims are drugs requiring approval. Research reagents for institutional use are separate.
Enforcement examples and uncertainty
CDSCO has not specifically targeted "research peptide" vendors at the same scale as US/EU regulators.
Uncertainty: the unfinalised e-pharmacy rules create enforcement gaps for online peptide sales. State-level enforcement is uneven.
Practical interpretation limits
This is general regulatory research, not legal advice. Classification can turn on composition, claims, intended use, route, supplier role, and facts not captured by a product name.
Related atlas pages: China, global framework, cross-border supply, and research governance.
Primary sources
CDSCO. https://cdsco.gov.in
Drugs and Cosmetics Act, 1940. https://cdsco.gov.in (legislation section).
NDCT Rules, 2019. https://cdsco.gov.in
Form 11 / Form CT-25 guidance. https://cdsco.gov.in (import/export section).